VIDEO: New dual heart-failure formulation scores several benefits

BARCELONA – It’s been a while since physicians had a new treatment for heart failure patients with reduced ejection fraction that makes them feel better, stay out of hospital, and live longer. But the investigational drug LCZ696 did just that in PARADIGM-HF, a controlled, pivotal trial with more than 8,000 patients, Dr. John McMurray said at the annual congress of the European Society of Cardiology.

In addition to robustly beating the comparator drug enalapril with reduced rates of both cardiovascular deaths and the combined endpoint of cardiovascular deaths and heart-failure hospitalizations, the new LCZ696 combination drug boosted patients’ quality of life in several clinically meaningful ways. The magnitude of the quality of life effect matched that seen in prior, successful, heart-failure treatment trials, Dr. McMurray, a professor of medical cardiology at the University of Glasgow, said in an interview.

He stressed that the combination of sacubitril, a new drug that inhibits neprilysin and thereby boosts levels of endogenous vasoactive peptides, and the well-established angiotensin-receptor blocker valsartan helped patients with milder, New York Heart Association class II heart failure, roughly 70% of enrolled patients. Activity in these less severely ill patients means that treatment with LCZ696 can "keep these patients stable, feeling well, functional, and out of the hospital as well as improve their survival," he said.

PARADIGM-HF was sponsored by Novartis, the company developing LCZ696. Dr. McMurray said that he has received travel support from Novartis.

mzoler@frontlinemedcom.com

Twitter: @mitchelzoler

BARCELONA – It’s been a while since physicians had a new treatment for heart failure patients with reduced ejection fraction that makes them feel better, stay out of hospital, and live longer. But the investigational drug LCZ696 did just that in PARADIGM-HF, a controlled, pivotal trial with more than 8,000 patients, Dr. John McMurray said at the annual congress of the European Society of Cardiology.

In addition to robustly beating the comparator drug enalapril with reduced rates of both cardiovascular deaths and the combined endpoint of cardiovascular deaths and heart-failure hospitalizations, the new LCZ696 combination drug boosted patients’ quality of life in several clinically meaningful ways. The magnitude of the quality of life effect matched that seen in prior, successful, heart-failure treatment trials, Dr. McMurray, a professor of medical cardiology at the University of Glasgow, said in an interview.

He stressed that the combination of sacubitril, a new drug that inhibits neprilysin and thereby boosts levels of endogenous vasoactive peptides, and the well-established angiotensin-receptor blocker valsartan helped patients with milder, New York Heart Association class II heart failure, roughly 70% of enrolled patients. Activity in these less severely ill patients means that treatment with LCZ696 can "keep these patients stable, feeling well, functional, and out of the hospital as well as improve their survival," he said.

PARADIGM-HF was sponsored by Novartis, the company developing LCZ696. Dr. McMurray said that he has received travel support from Novartis.

mzoler@frontlinemedcom.com

Twitter: @mitchelzoler

BARCELONA – It’s been a while since physicians had a new treatment for heart failure patients with reduced ejection fraction that makes them feel better, stay out of hospital, and live longer. But the investigational drug LCZ696 did just that in PARADIGM-HF, a controlled, pivotal trial with more than 8,000 patients, Dr. John McMurray said at the annual congress of the European Society of Cardiology.

In addition to robustly beating the comparator drug enalapril with reduced rates of both cardiovascular deaths and the combined endpoint of cardiovascular deaths and heart-failure hospitalizations, the new LCZ696 combination drug boosted patients’ quality of life in several clinically meaningful ways. The magnitude of the quality of life effect matched that seen in prior, successful, heart-failure treatment trials, Dr. McMurray, a professor of medical cardiology at the University of Glasgow, said in an interview.

He stressed that the combination of sacubitril, a new drug that inhibits neprilysin and thereby boosts levels of endogenous vasoactive peptides, and the well-established angiotensin-receptor blocker valsartan helped patients with milder, New York Heart Association class II heart failure, roughly 70% of enrolled patients. Activity in these less severely ill patients means that treatment with LCZ696 can "keep these patients stable, feeling well, functional, and out of the hospital as well as improve their survival," he said.

PARADIGM-HF was sponsored by Novartis, the company developing LCZ696. Dr. McMurray said that he has received travel support from Novartis.

mzoler@frontlinemedcom.com

Twitter: @mitchelzoler